10% Owner GV 2021 GP buys 1,500,000 shares at $3.30 in unprofitable biotech PRME; cluster of 3 other insiders buying within 14 days.
GV 2021 GP, a 10% shareholder, purchased 1,500,000 shares at $3.30 on 2025-08-01, expanding its stake by 85.1% to 3,262,440 shares (3.26M shares), a substantial commitment of $4,950,000.00 ($5.0M) in a company with a market cap of $573,756,763.98 ($573.8M). The company is unprofitable, reporting a net income of $-51,890,000.00 ($-51.9M) on quarterly revenue of $1,454,000.00 ($1.5M), indicating early-stage development with significant cash burn. The timing of this purchase aligns with a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated alignment among company stakeholders on near-term value despite the company's loss position. The current price of $4.37 reflects a 30-day gain of +40.5% and a 90-day gain of +207.8%, though it remains -22.1% below the 52-week high of $5.61.